# Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA

> **NCT00418717** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** etanercept

## Key facts

- **NCT ID:** NCT00418717
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2012-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418717, "Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00418717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*